Navigation Links
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Date:12/1/2011

TARRYTOWN, N.Y., Dec. 1, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a time change for the Company's presentation at the 2011 Deutsche Bank BioFEST scheduled for Monday, December 5, 2011.  The presentation is scheduled for 1:05 p.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through January 4, 2012. 

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.847.7799914.847.7640michael.aberman@regeneron.compete
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
2. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
3. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
4. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
5. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
6. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
7. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
8. Regeneron Reports Second Quarter 2011 Financial and Operating Results
9. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
10. Trading in Regeneron Common Stock Halted
11. Regeneron Reports First Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Implicit Bioscience Ltd and CMC ICOS Biologics today announced ... next stage of development and commercialization of IC14, a ... IC14 has a demonstrated safety profile in over 150 ... trial in mechanically-ventilated patients has provided a clear rationale ...
... Science is largely a collaborative enterprise. Frequently researchers ... pool their efforts and exchange ideas, to devise ... such as those known as autism spectrum disorders, ... on diverse populations of patients, finding a broader ...
Cached Medicine Technology:CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 2CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 3CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License 4Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4
(Date:7/12/2014)... New York, New York (PRWEB) July 12, 2014 ... involving liver damage allegations continue to move forward ... District Court, Eastern District of Pennsylvania, Bernstein Liebhard ... 1, 2014, U.S. District Judge Lawrence F. Stengel ... president. Among other things, Judge Stengel found that ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... July 12, 2014 “After my mom’s stroke, she ... a stroke and loss the use of his left side. Eating ... a way to help people like them enjoy eating again,” said ... prototype for the PATRICIA CAROL HALL PLATE (P C H PLATE). ... a more ergonomic way to eat for individuals who suffer from ...
(Date:7/12/2014)... 12, 2014 With prom shopping reaching ... and retailer, is ready to showcase its new and ... collection of evening dresses in its online shop. Additionally, ... off) for these elegant gowns. According to the company’s ... on July 26, 2014. , He says, “Now, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... At the 54th Annual Meeting of SNM, the ... medicine professionals, German researchers stated that early ... identifies patients responding to chemotherapy for esophageal cancer. ... apply PET results from early metabolic response assessment ...
... Secretary Mike Leavitt announced today that HHS has awarded a ... Denmark to manufacture and deliver 20 million doses of ... ,The vaccine would be recommended in the event of ... who have weakened immune systems. The full supply of the ...
... Center for Consumer Freedom (CCF) welcomed a new study ... & Adolescent Medicine, which will contribute to the steadily ... television food advertising and childhood obesity. A report issued ... similar results. ,The Archives study found that ...
... Pharmion Corporation today released interim findings from its ... company's third-generation synthetic anthracycline currently in development ... ,These findings indicate favorable interim results ... comparing Amrubicin to the current treatment standard, topotecan, ...
... by researchers at the Duke University Medical Center has found ... 3-fatty acids and fiber-related compounds known as lignans, is ... also think that the seed, which is similar to a ... events that leads cells to divide irregularly and become cancerous. ...
... why some people get anxious, or really scared when faced ... Well researchers at the European Molecular Biology Laboratory (EMBL) ... a new research they conducted on mice. ,They ... that could be potentially dangerous but not necessarily so, as ...
Cached Medicine News:Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:New Studies: Commercials Aren't Making Kids Fat 2Health News:Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment 2Health News:Flaxseed Helps in Reducing the Risk of Prostate Tumor Spread 2Health News:Researchers Have Found Clue to How Fear Changes into Phobia 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: